Skip to main content

Table 1 Trials' Characteristics

From: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Authors Pts Prior chemotherapy lines for metastatic disease Arms > 3 sites No adjuvant Chemo Visceral site Hormonal Receptors Negative (RN) Prior taxanes (T) Prior Anthra (A)
Miller et al 462 Mostly 1-2 Cap (2,500 mg/m2/day, days 1-14)
Cap (2,500 mg/m2/day, days 1-14) + Beva (15 mg/kg)
49.7% NR 78.7% NR 100% 100%
Gray et al 722 0 wPac (90 mg/m2 day 1, 8 and 15)wPac (90 mg/m2 day 1, 8 and 15)+ Beva (10 mg/kg) 45.7% 34.2% 62.2% 36.7% 14.9% 37.2%
Miles et al 736 0 Doc (100 mg/m2)
Doc (100 mg/m2)+ Beva 7.5 (7.5 mg/kg)
Doc (100 mg/m2)+ Beva 15 (15 mg/kg)
35.0%
33.4%
54.8%
54.9%
NR 17.1%
17.1%
14.9%
16.2%
53.7%
53.5%
Dieras et al 622 615 0 A/T
A/T + Beva (15 mg/kg)
Cap (2,000 mg/m2/day, days 1-14)
Cap (2,000 mg/m2/day, days 1-14) + Beva (15 mg/kg)
54.5%
27.8%
45.2%
43.9%
70.4%
68.8%
24.0%
23.6%
15.0%
39.5%
29.9%
62.9%
Bruwski et al 684 1 Chemo
Chemo + Beva
45.3% NR 73.1% 27.7% NR NR
  1. Pt: patients; RN: receptor negative; T: taxanes (3-weekly Docetaxel or protein-bound paclitaxel); Anthra (A): anthracyclines (various regimens: AC, EC, FAC, FEC); Cap: capecitabine; Beva: Bevacizumab; NR: not reported; wPac: weekly paclitaxel; Doc: docetaxel; Chemo: various chemotherapies.